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Abstract 
We have previously shown that estrogen exert a vasoprotective effect by accelerating 
reendothelialization after perivascular artery injury, through the activation of the estrogen 
receptor alpha (ERα). Since E2 is known to increase the bioavailability of nitric oxide, we 
used the same model in this study to characterize the role of the eNOS pathway in this 
process.  
Surprisingly, we found that the effect of 17β-estradiol (E2) on reendothelialization was not 
altered after pharmacological inhibition of NOS enzymatic activity by N-nitro-L-arginine 
methyl ester (L-NAME), whereas it was abolished in eNOS deficient (eNOS-/-) mice. This 
discrepancy between eNOS gene inactivation and the pharmacological inhibition of eNOS 
was confirmed in the more classical model of endovascular injury. When assessing the 
involvement of eNOS protein in short-term membrane-associated signaling events induced 
by E2, we found that E2 stimulates the phosphorylation of ERK1/2 in isolated perfused carotid 
arteries from wild-type mice, in the absence or in presence of L-NAME, whereas this effect 
was abolished in carotid artery from eNOS-/- mice. Similar results were obtained on mouse 
aortic endothelial cells in primary culture. 
These data reveal an original and unexpected role of eNOS, where its presence but not its 
enzymatic activity appears determinant for estrogen signaling in the endothelium. The 
consequences of this novel function of eNOS in vascular diseases should now be explored. 
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Introduction 
 
The endothelium is a major regulator of vascular homeostasis, influencing vascular 
tone and exerting anticoagulant, anti-platelet adhesion/aggregation, and fibrinolytic activities. 
Loss of endothelial monolayer integrity represents an important early step in atherosclerotic 
plaque development, and likewise endothelial destruction provoked by endoluminal 
angioplasty is a major effector of the subsequent restenosis1.  
17β-estradiol (E2) exerts several vasoprotective effects, such as vascular healing. We 
previously demonstrated that E2 accelerates reendothelialization2 and E2 was also shown to 
prevent neointimal hyperplasia in rats3 and medial hyperplasia in mice4. In addition, E2 
promotes vasorelaxation and inhibits platelet aggregation through potentiation of endothelial 
NO and prostacyclin production. Indeed, E2 stimulates endothelial NO synthase (eNOS) 
activity acutely through a membrane-derived non-genomic effect5, 6. E2 also increases NO 
bioactivity chronically through a decreased breakdown of NO, as a consequence of a 
reduced production of reactive oxygen species7, 8.  
The effects of E2 can be mediated by estrogen receptor alpha (ERα) or beta (ERβ), 
two members of the nuclear receptor superfamily that are encoded by 2 distinct genes9. We 
and others previously showed that ERα, but not ERβ, is responsible for important vascular 
effects of E2 such as NO production10-12  and arterial healing2, 13. Although ERs are classically 
defined as ligand-activated transcription factors14, it has become clear that short-term 
“extragenomic” responses play an important role in cultured endothelial cells, leading to 
PI3kinase-AKT and eNOS activation6, 10, 15. Both eNOS and a fraction of ERα are present in 
caveolae. Even though, to date, no direct interaction between the two proteins have been 
reported, they appear to be organized into a functional signaling complex in caveolae16.  
Losordo and colleagues17 previously showed that the accelerating effect of E2 on 
vascular reendothelialization is abolished in eNOS-/- mice, demonstrating the implication of 
eNOS. Concomitantly, we observed a persistence of the E2 effect on reendothelialization in a 
perivascular injury model using a pharmacological approach where eNOS was inhibited by L-
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NAME (N-nitro-L-arginine methyl ester). We have pursued this initial and contradictory 
observation through more thorough studies using both pharmacological inhibition of NOS 
activity by L-NAME and mice deficient in eNOS in both endovascular and perivascular injury 
models. In both models, we confirmed that the accelerating effect of E2 was abolished in 
eNOS-/- mice, but also unexpectedly that the effect of E2 was unaltered after pharmacological 
inhibition of NOS activity. A similar discrepancy was also observed on the phosphorylation 
status of MAP kinases, ERK1 and ERK2, after E2 treatment in an ex vivo model of isolated 
perfused carotid artery and in vitro in primary culture of mouse aortic endothelial cells. Thus, 
these data argue for a crucial role of eNOS which is independent of its nitric oxide synthase 
activity in the mediation of the estrogen effect in mouse carotid artery.  
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Materials and Methods 
 
Animals 
The investigation was in agreement with the Guide for the Care and Use of 
Laboratory Animals published by the US National Institutes of Health. The mice were housed 
in stainless steel cages in groups of 5, kept in a specific pathogen free facility. C57Bl/6J wild 
type mice were purchased from Charles River (France). eNOS-/- mice18 and ERα-/- mice19 
were maintained in our animal facility.  
For all surgical procedures, female mice were anesthetized by intraperitoneal 
injection of a mixture of ketamine and xylasine and allowed to recover on a 37°C heat pack. 
They were ovariectomized at 4 weeks of age and given or not 60-day time-release E2 pellets 
(0.1mg E2, releasing 80µg/kg/d) (Innovative Research of America, Sarasota, FL) implanted 
subcutaneously into the backs of the animals with a sterile trochar. The NOS inhibitor, nitro-
L-arginine methyl ester (L-NAME) (Sigma) (50 mg/kg/d) was given in the drinking water after 
ovariectomy. Electric carotid artery injury was performed 2 weeks later, in 6-week-old mice.  
 
cGMP measurements 
cGMP (the second messenger of NO) content in the thoracic aorta, the lung and the 
cerebellum was measured to assess the level of inhibition of NO synthase activity. Mice 
given L-NAME (0 or 50mg/kg/d) (8 mice in each group) were killed with an overdose of 
ketalar and used for determination of cGMP (the second messenger of NO) content in the 
thoracic aorta, in the lung and in the cerebellum. Thoracic aortae, lung and cerebella were 
removed and frozen in liquid nitrogen, and the tissues were stored frozen (-80°C) until 
measurement of the cGMP level. Frozen samples were thawed in glass potter in the 
presence of IBMX (10-4 M) and sonicated 10 times using ten 20 sec bursts. The 
homogenates were centrifuged (4000 rpm at 4°C during 15 min) and the supernatant fraction 
was taken for radioimmunoassay of cGMP using a commercial kit (Amersham). The samples 
were acetylated to increase the sensitivity of the assay. Data are the average of values from 
triplicate incubations. cGMP content was expressed as pmol per mg protein. 
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 Perivascular injury model 
The perivascular injury model was performed as previously described2. Briefly, the left 
common carotid artery was exposed via an anterior incision of the neck. The electric injury 
was applied to the distal part of the common carotid artery. The optimal conditions were 
determined as follows: electric power of 2 W applied for 2 seconds to each millimeter of 
carotid artery over a total length of 4 mm with the help of a size marker placed parallel to the 
long axis of the carotid.  
 
Endovascular injury model 
The endovascular injury model was adapted from Lindner et al.20. The right common 
carotid artery was exposed from the bifurcation, via an anterior incision of the neck. The 
external carotid was ligated distally and looped proximally with 8-0 silk suture. Silk loops 
were placed around the internal and common carotids to temporally restrict blood flow in the 
area of surgical manipulation. The ligature on the common carotid was precisely positioned 
against the sternocleidomastoid muscle 4 mm from the carotid bifurcation. This distance was 
very uniform from one animal to another. The external carotid artery was incised. The injury 
was performed using a 0.3 mm diameter swab built by loosely winding and sticking an 8-0 
silk suture around a 0.16 mm diameter blunted guide wire. The swab was introduced, 
advanced through the common carotid artery and withdrawn 3 times. A 4 mm length 
denudation from the bifurcation of the common carotid artery was performed using the silk 
ligature on the common carotid as injury limit. The device was removed and the external 
carotid ligated proximally. Blood flow was then restored by loosening the loops around the 
internal and common carotids. The skin incision was closed and animals were allowed to 
wake up under warm conditions. 
 
Quantification of endothelial regeneration 
Three or five days after injury, the endothelial regeneration process was evaluated by 
staining the denuded areas with Evans blue dye (Sigma, Saint Quentin Fallavier, France) as 
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previously described2. Briefly, the common carotid artery was dissected with an adjacent 
portion of the aortic arch and carotid bifurcation. The artery was then opened longitudinally 
and placed between slides with Fluoprep (BioMérieux, Marcy l’Etoile, France). The ratio 
between the area stained in blue and the total carotid artery area was calculated. The 
surface of the area that remained deendothelialized was indexed to the total carotid artery 
area to take into account the changes in vessel area due to both elasticity of the carotid 
artery and the flattening of the vessel between slides.  
 
Organ culture 
Female mice between 8 and 10 weeks of age were sacrificed by a lethal injection of 
sodium pentobarbital (50 mg/kg IP). Carotid arteries were immersed in an organ culture bath 
filled with Dulbecco’s modified Eagle’s medium containing antibiotics (100UI/L penicillin, 100 
mg/L streptomycin and 10 µg/L fungizone) and supplemented with 5% steroid-free fetal calf 
serum. Each arterial segment was maintained for 72h in a closed perfusion circuit described 
previously21, exposed to an intraluminal hydrostatic pressure of 80 mmHg with continuous 
renewal of medium within the intraluminal space at minimal shear stress (0.5 dynes/cm2). 
Organ culture of the carotid segments was carried out under sterile conditions in an incubator 
containing 5% CO2 at 37°C. At the end of the organ culture period, 10nM E2 (Sigma) or 
vehicle (DMSO) was injected in the intraluminal compartment for 15-60 min, in the presence 
(100µM) or absence of L-NAME. Thereafter vessels were quickly removed and processed as 
described below.  
 
Cultured endothelial cells.   
Endothelial cells (EC) were obtained from aorta according to the primary explant 
procedure adapted from a previously described protocol22, allowing the isolation of limited but 
pure cell preparations. Serum-starved EC were exposed for the indicated periods of time to 
E2 (10nM) in the presence or absence of L-NAME (100µM) or NG-Monomethyl-L-arginine 
acetate (L-NMMA) (Sigma)(100 and 300µM). 
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 Western Blot 
Cultured vessels were ground in ice-cold lysis buffer containing 20mmol/L Tris-HCl 
(pH 7.5), 5 mmol/L EGTA, 150 mmol/L NaCl, 20 mmol/L glycerophosphate, 10mmol/L NaF, 
1mmol/L sodium orthovanadate, 1% Triton X-100, 0.1% Tween 20 and protease inhibitors 
(Roche, Neuilly-sur-Seine, France). Detergent-soluble fractions were retained, and protein 
concentrations in samples were measured using a Bradford protein assay (Bio-Rad, Marnes-
la-Coquette). For western blot analysis, lysates containing 30µg of protein were 
electrophoresed on polyacrylamide gels and transferred to PVDF membranes (Amersham, 
Piscataway, NJ). Membranes were incubated with anti-phospho-ERK1/2, anti ERK1/2 (Cell 
Signaling Technology, Beverly, MA) or anti-ERK2 antibodies (Santa Cruz, Heidelberg, 
Germany). An enhanced chemiluminescence system was used as the detection method 
(ECL+, Amersham). 
 
Immunohistochemical analysis 
Arteries were embedded in paraffin and sections perpendicular to the long axis of the 
carotid were cut at the level of the reendothelialized area of the injured carotid artery. 
Sections were subjected to standard hematoxylin/eosin staining and to eNOS 
immunodetection. Detection of eNOS expression was determined with rabbit polyclonal anti-
eNOS (1:200; Santa Cruz Biotechnology, Cat# sc-654). The specificity of eNOS antibody 
was tested on carotid artery cross sections from eNOS-/- mice.  
 
Statistics 
Data are expressed as mean±SEM. For cultured vessels, western blot band density 
was quantified using Image Gauge software (Fuji). One-way ANOVA (or two-way) was used 
to compare data for different genotypes or inhibitors. When ANOVA analyses yielded 
significant results, comparisons were done using Bonferroni’s test. 
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 Results 
 
eNOS, but not NO production, is required for the effect of E2 on reendothelialization. 
To define the role of NO production in the stimulating effect of E2 on 
reendothelialization in the perivascular injury model, we first used a pharmacological 
approach; ovariectomized wild type C57Bl/6J mice were treated chronically with L-NAME 
(50mg/kg/d). As shown in Figure 1A, pharmacological inhibition of eNOS activity did not alter 
the accelerating effect of E2 on reendothelialization 5 days post-injury. Similar results were 
obtained at day 3 post-injury (not shown). Similar results were also obtained at day 5 post-
injury in C57Bl/6J mice treated chronically with a two-fold higher dose of L-NAME 
(100mg/kg/d; not shown). 
As these results were inconsistent with a previous study by Losordo and colleagues17, 
implicating eNOS in the E2 effect on reendothelialization, we decided to repeat the study in 
the endovascular injury model. As observed in the perivascular injury model, treatment with 
L-NAME did not influence the capacity of E2 to speed up reendothelialization in the 
endovascular injury model (Figure 2A). In order to verify that the dose of L-NAME used 
(50mg/kg/d) efficiently blocked NO production in our experiments, the cGMP content in the 
thoracic aorta of C57Bl/6J mice treated with L-NAME (0 or 50mg/kg/d) for 8 days were 1.06 ± 
0.05 and 0.35±0.03 pmol/mg protein respectively (P<0.0001), demonstrating a 3-fold drop in 
the second messenger of NO in L-NAME treated mice.   
The cGMP content in the lung of C57Bl/6J mice given placebo or L-NAME 50mg/kg/d 
were 0.22±0.04 and 0.11±0.02 pmol/mg protein, respectively (P<0.001). These decreased 
levels of vascular cGMP were not further altered by doubling the dose of L-NAME (i.e. 100 
mg/kg/d for 8 days), strongly suggesting that the dose of 50mg/kg/d used else in this study 
as well as in previous works23, 24 maximally blocks the eNOS activity. Moreover, we observed 
a 4.5-fold drop in cGMP in cerebellum preparations from L-NAME treated mice, 
demonstrating an inhibition of neuronal NOS (not shown). 
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Taken together, our data show that inhibiting NO production with L-NAME did not 
influence the effect of E2 on endothelial regrowth in vivo, irrespective of the arterial injury 
model. 
The divergence between our findings and those previously published17 prompted us 
to reassess the role of eNOS five days after injury using a transgenic approach. Indeed, in 
agreement with the reported data, the accelerating effect of E2 on reendothelialization was 
abolished in eNOS-/- mice, both in the perivascular injury model (Figure 1B) as in the 
endovascular injury model (Figure 2B). Again, similar results were obtained at day 3 post-
injury (not shown). 
As shown in Figure 1B and 2B, the absence of E2 effect on reendothelialization was 
confirmed in these animals, and no “additional” effect of L-NAME was observed in either 
vascular injury model. 
Altogether, these data showed that in vivo, eNOS, but not NO production, is required 
for the accelerating effect of E2 on reendothelialization. 
 
eNOS expression is enhanced in the reendothelialized intimal area. 
Given the importance of the eNOS protein in the reendothelialization process, we 
next performed immunohistochemical analyses to compare its expression levels in injured 
and uninjured carotid arteries. Compared with the endothelium of an intact (uninjured) artery 
(Figure 3A), eNOS expression was clearly enhanced in the regenerated endothelium of 
healing carotid artery, day 5 post-injury in wild type mice (Figure 3B), in agreement with 
previous observations made in regenerated endothelium in rat25 and in proliferating cultured 
endothelial cells26. In this electric injury model, the regenerated endothelial area can be 
easily recognized by the characteristic absence of underlying smooth muscle cells. The 
expression of eNOS was restricted to the intima in both intact and injured vessels, 
suggesting that it was mainly expressed at the level of the endothelium even after injury. As 
anticipated, no eNOS specific staining was detected in arteries of eNOS-/- mice (Figure 3C 
and 3D). 
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eNOS, but not NO production, is required for E2-induced ERK1/2 phosphorylation in 
isolated perfused carotid artery and primary culture of mouse aortic endothelial cells.  
We then sought to explore the respective roles of eNOS deficiency and eNOS 
enzyme inhibition in E2-induced ERK1/2 activation, using an ex vivo model. As shown in 
Figure 4, ERK1/2 phosphorylation was enhanced in wild type carotid arteries exposed to E2, 
reaching an activation peak at 30 min and declining at 60 min. A delayed ERK1/2 activation 
have previously been reported in cultured endothelial cells exposed to E227. We also found 
that ERK1/2 phosphorylation by E2 was preserved in carotid arteries from wild type mice 
treated with 100 µM L-NAME, demonstrating that E2 acted independently of NO production. 
In contrast, E2-induced ERK1/2 activation was abolished in carotid arteries from eNOS-/- 
mice. Similarly, E2 failed to induce ERK1/2 phosphorylation in carotid arteries from ERα-/- 
mice.  
We then reassessed the respective roles of eNOS deficiency and eNOS enzyme 
inhibition in cultured endothelial cells from mouse aortae. As shown in Figure 5, we found 
that E2 stimulated the phosphorylation of ERK1/2 equally in untreated and in L-NAME- 
treated cells from WT mice. L-NMMA, another NOS inhibitor, did not alter the effect of E2 
stimulated the phosphorylation of ERK1/2 in endothelial cells from WT mice (not shown). 
Moreover, pretreatment with 0.5 mM DPTA NONOate, a NO donor, did not restore the effect 
of E2 in endothelial cells from eNOS-/- mice (not shown). On the other hand, activation of 
ERK1/2 by E2 was abolished in eNOS-/- and ERα-/- cells. A deficiency in intracellular BH4 
levels does not appear to explain these differences, since neither the supplementation of 
BH4 (3µM) nor of the BH4 synthesis substrate sepiapterin (50 µM) to cultured aortic 
endothelial cells from C57BL/6 wild-type mice altered the phosphorylation of ERK1/2 in 
response to E2 (not shown). 
As gene inactivation is known to favor gene expression remodeling, in particular 
“gene compensations”, we tried to restore eNOS expression in eNOS-deficient endothelial 
cells through transfection. However, we did not succeed with this approach due to the 
difficulty of transfecting these fragile cells, which underwent apoptosis soon after 
transfection.   
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We therefore sought to abolish eNOS expression in eNOS-expressing endothelial 
cells using siRNA against eNOS. We first performed this experiment in endothelial cells from 
eNOS +/+ mice, but again these cells did not tolerate transfection. We next tried a more 
classical cell model of endothelial cells: HUVECs. Unfortunately, we were unable to elicit 
ERK1/2 activation in response to E2 in HUVEC, even in freshly harvested cell at very early 
passages. This was likely due to lack of ER gene expression (assessed by RT-PCR and 
Western blotting) at variance with previous work28, but in agreement with other29. 
Finally, we tried a HUVEC derived cell line (EA.hy926) that has been shown to 
express ERα30. In this model, we were able to elicit MAPK activation in response to E2, and a 
clear decrease of this signal after eNOS siRNA treatment (Fig I, supplementary data). These 
data indicate that the level of eNOS protein expression influence the capacity of E2 to 
activate ERK1/2 in vitro. However, we were struck by the poor reproducibility of this model, 
as in two out of four experiments, we did not observe an increase in ERK1/2 phosphorylation 
in response to E2 in control cells. 
Altogether, these data suggest that the E2 effect leading to ERK1/2 phosphorylation is 
mediated by ERα and appears to be strictly dependent on the presence of eNOS protein, but 
not its activity, in both ex vivo and in vitro models. Noteworthy, the reproducibility of the 
effects observed in vivo or ex vivo was much more robust than the ones observed in cultured 
endothelial cells. 
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Discussion 
Altogether, our results reveal an original and unexpected role for eNOS in endothelial 
regeneration and in plasma membrane E2 signaling, acting as a signaling protein 
independently of its NO-producing function. Indeed, our finding that accelerated 
reendothelialization induced by E2 was abolished in eNOS-/- mice agreed with a previous 
report17, but we were surprised to observe that the pharmacological inhibition of NOS with L-
NAME had no influence on the beneficial effect of E2 in two models of vascular injury.  
Our finding that the in vivo effects of E2 differ between L-NAME-treated and eNOS-/- 
mice appears robust for the following reasons: 1) it was established in two different 
experimental models, endovascular and electric perivascular carotid artery injury; 2) 
pharmacological inhibition of eNOS using L-NAME was previously shown to maximally block 
NO synthase activity23, 24, 31, and its efficacy was verified in the present work; 3) abrogation of 
the effect of E2 by eNOS gene inactivation has now been demonstrated independently, since 
the eNOS-/- model used in the present work18 was different from that used by Losordo and 
colleagues32. 
To better understand the interaction between E2 and eNOS, we explored the 
respective influences of eNOS gene inactivation and eNOS activity inhibition on the short-
term effects of E2 in an ex vivo artery model. This model was used to specifically study 
endothelium in its native matrix and mechanical (submitted to physiologic pressure) 
environment, in the absence of confounding hormonal or circulating factors encountered in 
vivo33. As previously described in cultured human, bovine and porcine endothelial cells27, 34, 
35, we found that E2 induced ERK1/2 activation in isolated perfused carotid arteries. 
Interestingly, and in agreement with our reendothelialization data, the plasma membrane 
signaling of E2 was strictly dependent on the presence of eNOS protein, but not eNOS 
activity in isolated perfused carotid arteries. The limitation of this model in interpreting 
ERK1/2 activation is that both endothelial and smooth muscle cells express ERK1/2. 
However, the exclusive expression of eNOS in the endothelium (Fig 3) on the one hand, and 
the similarity in results between in vivo and ex vivo models on the other hand, reinforce the 
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concept that plasma membrane signaling of E2 is strictly dependent on the presence of 
eNOS protein, but not eNOS activity, in the endothelial cells of carotid arteries. 
eNOS gene disruption and NOS pharmacological inhibition are often viewed as 
comparable strategies, as they in some aspects generate similar results, such as the 
induction of hypertension and endothelial dysfunction18, 23, 24, 31, 32. However, discrepancies 
between these two models have already been suggested, but never directly demonstrated. 
For instance, eNOS-/-apoE-/- mice develop two-fold more fatty streak lesions than apoE-/- 
mice36 whereas inhibition of NO production by L-NAME does not influence fatty streak 
deposit in apoE-/- mice24, 36. Similarly, de Mey and colleagues previously showed an 
abrogation of shear stress induced vascular remodeling in eNOS-/- mice37 , but not in L-
NAME treated rats38, suggesting that eNOS, but not eNOS activity, could play a role in 
vascular remodeling. This kind of dissociation between protein expression and enzymatic 
activity was nicely demonstrated for PI3Kγ39 which participates in two distinct signaling 
cascades: a kinase-dependent pathway that controls PKB/AKT activity, and a kinase-
independent pathway that relies on protein interactions with a phosphodiesterase to 
negatively modulate cardiac contractility. 
Since eNOS is largely present in caveolae and a fraction of ERα is also localized in 
this membrane compartment, these two molecules could associate in a functional molecular 
complex16 30. Moreover, both ERα and eNOS were shown to interact with HSP9040 and 
caveolin 141, 42, which reinforces the probability of a caveolar interaction of these proteins and 
supports of the hypothesis that eNOS acts in a multi-protein assembly, allowing ERK1/2 
activation in response to E2. 
Even though L-NAME is not a specific inhibitor of eNOS, but also inhibits other NOS 
isozymes, such as neuronal NOS (nNOS) and to some extent inducible NOS (iNOS), the 
lack of specificity could hardly be influencing our conclusions concerning the effects on the 
carotid artery. Indeed, the inhibition of iNOS by L-NAME is only partial in vivo at the dose 
used in the present study43, 44. However, L-NAME did not alter the observed loss of E2 effect 
in eNOS-/- mice, ruling out an inference of the other NOS isoforms in the abrogation of the E2 
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effects in eNOS -/- mice.  Finally, a significant contribution of superoxide production by eNOS 
uncoupling is unlikely since, 1) BH4 supplementation did not influence the result observed in 
wild-type cultured cells; 2) L-NAME inhibits superoxide production, as demonstrated in 
previous in vivo45 and ex vivo46 studies; 3) L-NAME inhibits superoxide production of purified 
nNOS 47, 48.  
The in vivo effects of E2 probably involve both genomic and non-genomic 
mechanisms. Although ERs are classically defined as ligand-activated transcription factors14, 
it has become clear that short-term “extragenomic-to-genomic” responses play an important 
role in cultured endothelial cells6, but also in osteoblasts and in cortical neurons (as for 
instance the activation of PI3kinase-AKT pathways as well as MAP kinase pathways)49, 50. 
The characterization of the respective roles of these “membrane” and “classical” effects 
represents an important but difficult challenge for the next years15, 51, 52. 
Beyond this unexpected role of eNOS in E2 signaling, the clinical implications of our 
observations could be significant. First, the strong correlation between our in vivo and ex vivo 
findings support an implication of plasma membrane estrogen signaling in its protective 
effects. Second, given that deficiency in E2 has been recognized to modulate endothelial 
function53, altered eNOS expression or trafficking in the context of endothelial dysfunction 
could hinder the beneficial effects of E2, thus sustaining a vicious circle. This could for 
instance help to explain the highly negative relationship reported between smoking and 
estrogen atheroprotection54. Third, the proposed role of eNOS, acting within a molecular 
complex independently of its NO producing activity, may not be restricted to E2 signaling but 
may also influence endothelial response to other vasoactive compounds. These specific 
roles of eNOS should be more precisely explored in future work.  
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Figures legends: 
 
Figure 1. Perivascular injury model: effect of E2 on the reendothelialization process in 
ovariectomized wild type (A) and eNOS -/- (B) mice treated or not (placebo) with E2 (80 
µg/kg/d) and receiving or not L-NAME (50 mg/kg/d) in the drinking water. Results show 
percent deendothelialization calculated as ratio of remaining deendothelialized area to total 
carotid artery area, at day 5. *P<0.05 vs respective placebo group. 
 
Figure 2. Endovascular injury model: effect of E2 on the reendothelialization process in 
ovariectomized wild type (A) and eNOS -/- (B) mice treated or not (placebo) with E2 (80 
µg/kg/d) and receiving or not L-NAME (50 mg/kg/d) in the drinking water. Results show 
percent deendothelialization calculated as ratio of remaining deendothelialized area to total 
carotid artery area, at day 5. *P<0.05 vs respective placebo group. 
 
Figure 3. Immunostaining of eNOS in non injured (A, C) and reendothelialized (B, D) 
carotid arteries of wild type (A, B) and eNOS-/- mice (C, D) at day 5 after perivascular injury.  
 
Figure 4. Acute phosphorylation of ERK1/2 induced by E2 in carotid arteries from wild 
type mice is insensitive to L-NAME but is abolished in eNOS-/- carotid arteries.  A, 
Representative Western blot showing short-term phosphorylation kinetics of ERK1/2 induced 
by E2 (10nM), administered in the intraluminal compartment of carotid arteries after 3 days in 
organ culture. ERK1/2 phosphorylation is equivalent in untreated and L-NAME-treated 
(100µM) carotid arteries from WT mice, but abolished in carotid arteries from eNOS-/- and 
ERα-/- mice. B, Bar graph represents the quantification of the phospho-ERK1/2 / ERK2 ratio, 
normalized to the control within each group. *P<0.05 and ***P<0.001 vs respective control 
group. 
 
 23
Figure 5. eNOS deficiency prevents E2-induced ERK1/2 activation in MAECs. Isolated 
mouse endothelial cells were treated with E2 (10nM) for different times. A, Representative 
immunoblotting experiments show that phosphorylation of ERK1/2 is enhanced by E2 in 
endothelial cells from WT but not eNOS–/– or ERα–/– mice. B, Bar graph represents the 
quantification of the P-ERK/ ERK ratio, normalized to the control within each group (n=2 
experiments). 
 
Supplementary data. 
Figure I. Effect of siRNA-mediated eNOS knockdown on E2-induced ERK1/2 activation 
in EA.hy926 cells. Immunoblots from E2-treated EA.hy926 endothelial cells transfected with 
scramble or eNOS siRNA. The cell lysates were resolved by SDS-PAGE and analyzed in 
immunoblots probed as indicated with specific antibodies directed against eNOS, phospho-
ERK1/2, total ERK1/2. 
 
Materials and Methods 
siRNA transfection. Small interference RNA duplex oligonucleotides (ON-TARGET Plus) 
were from Dharmacon, Inc. (Lafayette, CO). EA.hy926 cells (courtesy of Edgell C. J.) were 
cultured as previously described 55 and transfected with siRNA (100nM) using LipofectAMINE 
2000 (Invitrogen) following the instruction provided by the supplier. Forty-eight hours later, 
cells were harvested and subjected to Western blot analysis as described in the main 
Material and methods section. The antibodies used were from Santa Cruz (anti-eNOS) and 
Cell Signaling Technology (anti-phospho-ERK1/2 and anti ERK1/2).  
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